Stock Movers: Cidara Therapeutics Surges on Merck Acquisition, Stubhub Tumbles, WBD Rallies Amid Sale Rumors

Cidara Therapeutics Acquisition by Merck

• 💡 Cidara Therapeutics (CDTX) shares surged over 100% following news that Merck has agreed to acquire the biotech company for approximately $9.2 billion.
• 🎯 The acquisition price is $221.50 per share in cash, aiming to bolster Merck's treatment portfolio as it faces significant patent expirations.
• 📈 Merck anticipates $18 billion in eroding sales over the next five years due to patent losses, including its best-selling cancer drug, Keytruda.
• 🤝 This follows Merck's previous acquisition of respiratory drug maker Verona for around $10 billion, highlighting a trend of competitive deals in the pharmaceutical industry.

Stubhub's Stock Drop Post-IPO

• 📉 Stubhub (STUB) shares fell as much as 22% after its first quarterly report since going public in September.
• ⚠️ The primary reason for the decline was the company's decision, stated by CEO Eric Baker, not to provide guidance for the current quarter, citing a long-term approach and unpredictability in ticket sale timings.
• ⏳ Stubhub plans to offer an outlook for 2026 when it reports fourth-quarter results, but investors reacted negatively to the lack of near-term financial projections.
• 📊 Analysts noted the high short interest on the stock, with 56% of the float potentially being shorted.

Warner Bros. Discovery (WBD) Sale Speculation

• 🚀 Warner Bros. Discovery (WBD) shares rallied on reports from The Wall Street Journal that Paramount, Comcast, and Netflix are preparing bids to acquire the media giant.
• 🗓️ An apparent cutoff for these bids is set for November 20th, with WBD aiming to finalize a deal by the end of the year.
• 💼 In a related move, WBD amended CEO David Zaslav's contract to ensure his stock options remain eligible to vest even if the company is sold.
• 🔍 This follows the company's prior announcement to explore strategic options, including a potential sale.